Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) General Counsel Jason B. Shandell sold 16,095 shares of the firm’s stock in a transaction dated Friday, November 9th. The shares were sold at an average price of $20.99, for a total value of $337,834.05. Following the completion of the transaction, the general counsel now directly owns 204,805 shares in the company, valued at $4,298,856.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
NASDAQ:AMPH traded up $0.88 during mid-day trading on Friday, reaching $21.59. The stock had a trading volume of 735,306 shares, compared to its average volume of 191,315. The company has a market capitalization of $889.51 million, a price-to-earnings ratio of 56.82, a price-to-earnings-growth ratio of 8.77 and a beta of 1.38. Amphastar Pharmaceuticals Inc has a 1-year low of $14.40 and a 1-year high of $21.65. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, November 8th. The company reported $0.12 EPS for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.01. The business had revenue of $75.54 million during the quarter, compared to the consensus estimate of $76.84 million. Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The company’s revenue for the quarter was up 30.5% compared to the same quarter last year. During the same period last year, the firm earned $0.07 earnings per share. On average, equities research analysts forecast that Amphastar Pharmaceuticals Inc will post 0.1 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of AMPH. BlackRock Inc. grew its stake in Amphastar Pharmaceuticals by 5.9% in the second quarter. BlackRock Inc. now owns 5,720,183 shares of the company’s stock worth $87,291,000 after purchasing an additional 318,360 shares in the last quarter. Federated Investors Inc. PA grew its stake in Amphastar Pharmaceuticals by 21.6% in the second quarter. Federated Investors Inc. PA now owns 1,276,552 shares of the company’s stock worth $19,480,000 after purchasing an additional 227,142 shares in the last quarter. Cortina Asset Management LLC grew its stake in Amphastar Pharmaceuticals by 49.9% in the second quarter. Cortina Asset Management LLC now owns 392,296 shares of the company’s stock worth $5,986,000 after purchasing an additional 130,604 shares in the last quarter. Martingale Asset Management L P acquired a new position in Amphastar Pharmaceuticals in the third quarter worth about $2,033,000. Finally, Dimensional Fund Advisors LP grew its stake in Amphastar Pharmaceuticals by 5.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,769,533 shares of the company’s stock worth $27,004,000 after purchasing an additional 84,085 shares in the last quarter. Institutional investors and hedge funds own 42.86% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Jason B. Shandell Sells 16,095 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock” was first posted by WKRB News and is owned by of WKRB News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/11/10/jason-b-shandell-sells-16095-shares-of-amphastar-pharmaceuticals-inc-amph-stock.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
See Also: Intrinsic Value
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.